본문 바로가기
KERD
논문KCI 등재

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment

Stephen L. Chan|Landon L. Chan
대한간학회 (The korean Association for the Study of the Liver)|2023.10|Clinical and Molecular Hepatology|제29권 제4호|pp. 909-923

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Hepatocellular carcinomaAntineoplastic agentsImmune checkpoint inhibitor

초록

Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior response rates and survival benefits based on recently published phase III trials. However, the role of first-line lenvatinib remains uncertain as no prospective trials have compared its efficacy with ICI in advanced HCC. Several retrospective studies have shown that first-line lenvatinib may not be inferior to ICI combination. Indeed, a growing body of evidence suggests that ICI treatment is associated with inferior treatment outcome in non-viral HCC patients, questioning the supremacy of ICI treatment in all patients and rendering first-line lenvatinib as a potential preferred treatment option. Furthermore, in high-burden intermediate-stage HCC, accumulating evidence supports first-line lenvatinib, or in combination with transarterial chemoembolization (TACE), as a preferred treatment option over TACE alone. In this Review, we describe the latest evidence surrounding the evolving role of first-line lenvatinib in HCC.

Abstract

Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior response rates and survival benefits based on recently published phase III trials. However, the role of first-line lenvatinib remains uncertain as no prospective trials have compared its efficacy with ICI in advanced HCC. Several retrospective studies have shown that first-line lenvatinib may not be inferior to ICI combination. Indeed, a growing body of evidence suggests that ICI treatment is associated with inferior treatment outcome in non-viral HCC patients, questioning the supremacy of ICI treatment in all patients and rendering first-line lenvatinib as a potential preferred treatment option. Furthermore, in high-burden intermediate-stage HCC, accumulating evidence supports first-line lenvatinib, or in combination with transarterial chemoembolization (TACE), as a preferred treatment option over TACE alone. In this Review, we describe the latest evidence surrounding the evolving role of first-line lenvatinib in HCC.

참고문헌 (75)

  1. Sung H, "Global cancer statistics 2020 : GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  2. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
  3. Johnson PJ, "Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma : results from the randomized phase III BRISK-FL study", J Clin Oncol, 31, pp.3517~3524 (2013)
  4. Cheng AL, "Sunitinib versus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial", J Clin Oncol, 31, pp.4067~4075 (2013)
  5. Cainap C, "Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma : results of a randomized phase III trial", J Clin Oncol, 33, pp.172~179 (2015)
  6. Zhu AX, "SEARCH : a phase III, randomized, double-blind, placebocontrolled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma", J Clin Oncol, 33, pp.559~566 (2015)
  7. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
  8. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
  9. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
  10. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebocontrolled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
  11. Finn RS, "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
  12. Abou-Alfa GK, "Phase 3 randomized, open-label, multicenter study of tremelimumab(T)and durvalumab(D)as first-line therapy in patients(pts)with unresectable hepatocellular carcinoma(uHCC) : HIMALAYA", J Clin Oncol, 44(4 suppl), pp.379~ (2022)
  13. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
  14. Cheng AL, "Updated efficacy and safety data from IMbrave150 : Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma", J Hepatol, 76, pp.862~873 (2022)
  15. Tohyama O, "Antitumor activity of lenvatinib(e7080) : an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models", J Thyroid Res, 2014, pp.638747~ (2014)
  16. Vogel A, "Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma : patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial", Lancet Gastroenterol Hepatol, 6, pp.649~658 (2021)
  17. Luo J, "Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma : A meta-analysis", Front Oncol, 12, pp.1010726~ (2022)
  18. Kudo M, "Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma", Hepatobiliary Surg Nutr, 11, pp.592~596 (2022)
  19. Postow MA, "Immune-related adverse events associated with immune checkpoint blockade", N Engl J Med, 378, pp.158~168 (2018)
  20. Brahmer JR, "Society for Immunotherapy of Cancer(SITC)clinical practice guideline on immune checkpoint inhibitorrelated adverse events", J Immunother Cancer, 9, pp.e002435~ (2021)
  21. Tison A, "Immunecheckpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases", Nat Rev Rheumatol, 18, pp.641~656 (2022)
  22. Toniutto P, "Liver transplantation in patients with hepatocellular carcinoma beyond the milan criteria : A comprehensive review", J Clin Med, 10, pp.3932~ (2021)
  23. Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
  24. Au KP, "Immunotherapy after liver transplantation : Where are we now?", World J Gastrointest Surg, 13, pp.1267~1278 (2021)
  25. Jiang J, "Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?", Front Immunol, 14, pp.1092401~ (2023)
  26. Weinmann A, "Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation", Dig Liver Dis, 44, pp.432~437 (2012)
  27. Sposito C, "Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation : a case-control study", J Hepatol, 59, pp.59~66 (2013)
  28. Alsina AE, "Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study", Am Surg, 80, pp.680~684 (2014)
  29. Chen YY, "Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study", Cancers(Basel), 13, pp.4584~ (2021)
  30. Bang K, "Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation", Cancer Med, 12, pp.2572~2579 (2023)
  31. Mazzarelli C, "Lenvatinib for treatment of recurrence hepatocellular carcinoma after liver transplantation : A case series", Dig Liver Dis, 55(Suppl 1), pp.S68~ (2023)
  32. de Franchis R, "Baveno VII-Renewing consensus in portal hypertension", J Hepatol, 76, pp.959~974 (2022)
  33. Thabut D, "Treatment of portal hypertension in patients with HCC in the era of Baveno VII", J Hepatol, 78, pp.658~662 (2023)
  34. Hidaka H, "Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma : A prospective cohort study", Hepatol Res, 50, pp.1083~1090 (2020)
  35. Allaire M, "Portal hypertension and hepatocellular carcinoma : Des liaisons dangereuses…", Liver Int, 41, pp.1734~1743 (2021)
  36. Maesaka K, "Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension", Hepatol Res, 50, pp.1091~1100 (2020)
  37. Fang P, "Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma : a systematic review of phase II trials", PLoS One, 7, pp.e49717~ (2012)
  38. Chuma M, "Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation : A multicenter analysis", Hepatol Res, 51, pp.201~215 (2021)
  39. Kuzuya T, "Sorafenib vs. Lenvatinib as first-line therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Anticancer Res, 40, pp.2283~2290 (2020)
  40. Breder V, "IMbrave150 : Exploratory efficacy and safety results of hepatocellular carcinoma(HCC)patients(pts)with main trunk and", or contralateral portal vein invasion(Vp4)treated with atezolizumab(atezo)+ bevacizumab(bev)versus sorafenib(sor)in a global Ph III study, 2021, pp.39(15 suppl), 4073~
  41. Kim BK, "Atezolizumab", Bevacizumab vs. Lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: A real-world, multi-center study, 2022, pp.14, 1747~
  42. Casadei-Gardini A, "Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma : a large real-life worldwide population", Eur J Cancer, 180, pp.9~20 (2023)
  43. Kuo YH, "Realworld lenvatinib versus sorafenib in patients with advanced hepatocellular carcinoma : A propensity score matching analysis", Front Oncol, 11, pp.737767~ (2021)
  44. Burgio V, "Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular carcinoma in Italy", Cancer Manag Res, 13, pp.9379~9389 (2021)
  45. Rimini M, "Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma : A multi-institutional matched case-control study", Hepatol Res, 51, pp.1229~1241 (2021)
  46. Tovoli F, "Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients", J Hepatol, 71, pp.1175~1183 (2019)
  47. Casadei Gardini A, "Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib", Clin Res Hepatol Gastroenterol, 43, pp.e76~e78 (2019)
  48. Finn RS, "LBA34Primary results from the phase III LEAP-002 study : Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L)therapy for advanced hepatocellular carcinoma(aHCC)", Ann Oncol, 33(Suppl 7), pp.S1401~ (2022)
  49. "Finn Reviews Phase 3 Trials of Lenvatinib in Advanced HCC"[URL]
  50. Chan LL, "P-108 : Impact of dose adjustment on clinical outcome of lenvatinibtreated patients with advanced hepatocellular carcinoma(HCC)", International Liver Cancer Association Conference (2022)
  51. Kelley RK, "Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312) : a multicentre, openlabel, randomised, phase 3 trial", Lancet Oncol, 23, pp.995~1008 (2022)
  52. Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC", Nature, 592, pp.450~456 (2021)
  53. Rimini M, "Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma : an international propensity score matching analysis", ESMO Open, 7, pp.100591~ (2022)
  54. Seul Ki Han, "Non-alcoholic fatty liver disease: Definition and subtypes", Clinical and Molecular Hepatology, 29, pp.5~16 (2023), 대한간학회
  55. Chan AW, "Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B", J Gastroenterol Hepatol, 32, pp.667~676 (2017)
  56. Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma : A phase III, randomized clinical trial(LAUNCH)", J Clin Oncol, 41, pp.117~127 (2023)
  57. Zhang S, "Transarterial chemoembolization failure", refractoriness : A scientific concept or pseudo-proposition, 2022, pp.14, 528~537
  58. Liu K, "The changes of HIF-1α and VEGF expression after TACE in patients with hepatocellular carcinoma", J Clin Med Res, 8, pp.297~302 (2016)
  59. Sergio A, "Transcatheter arterial chemoembolization(TACE)in hepatocellular carcinoma(HCC) : the role of angiogenesis and invasiveness", Am J Gastroenterol, 103, pp.914~921 (2008)
  60. Forner A, "Hepatocellular carcinoma", Lancet, 391, pp.1301~1314 (2018)
  61. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
  62. Arizumi T, "Time to transcatheter arterial chemoembolization refractoriness in patients with hepatocellular carcinoma in kinki criteria stages B1 and B2", Dig Dis, 35, pp.589~597 (2017)
  63. Marrero JA, "Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups : The GIDEON study", J Hepatol, 65, pp.1140~1147 (2016)
  64. Ganten TM, "Sorafenib in patients with hepatocellular carcinomaresults of the observational INSIGHT study", Clin Cancer Res, 23, pp.5720~5728 (2017)
  65. Iavarone M, "Field-practice study of sorafenib therapy for hepatocellular carcinoma : a prospective multicenter study in Italy", Hepatology, 54, pp.2055~2063 (2011)
  66. Kudo M, "Lenvatinib as an initial treatment in patients with intermediatestage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: A proof-of-concept study", Cancers(Basel), 11, pp.1084~ (2019)
  67. Kudo M, "Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma", Liver Cancer, 7, pp.1~19 (2018)
  68. Mazzaferro V, "Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria : a retrospective, exploratory analysis", Lancet Oncol, 10, pp.35~43 (2009)
  69. Ueshima K, "Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma(TACTICS-L)in Japan : Final analysis", J Clin Oncol, 40(4 suppl), pp.417~ (2022)
  70. Kudo M, "TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma", J Clin Oncol, 40(4 suppl), pp.TPS487~ (2022)
  71. Foerster F, "ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma", J Clin Oncol, 40(4 suppl), pp.TPS498~ (2022)
  72. Kudo M, "Atezolizumab plus bevacizumab followed by curative conversion(ABC Conversion)in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma", Liver Cancer, 11, pp.399~406 (2022)
  73. Yoo C, "Clinical outcomes with multikinase inhibitors after progression on firstline atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : A multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)
  74. Gile J, "Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma", J Clin Oncol, 41(4 suppl), pp.507~ (2023)
  75. Llovet JM, "Randomized phase 3 LEAP-012 study : Transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment", Cardiovasc Intervent Radiol, 45, pp.405~412 (2022)

관련 논문AI추천

Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter StudyBin Li, Deyi Liu, Han Li, Jianyin Zhou, Jiayi Wu, Junyi Wu, Kai Wang, Maolin Yan, Shaowu Zhuang, Shuang Qu, Shuqun Cheng, Shuqun Li, Xiangye Ou, Yangkai Fu, Yinan Li, Zhenxin Zeng, Zhibo Zhang대한암학회 · Cancer Research and Treatment2024 · 제56권 제4호Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study김도영, 김범경, 김승업, 박준용, 안상훈, 전영은, 전홍재, 하연정, Beodeul Kang, Dong Yun Kim, Joo Ho Lee, Jung Sun Kim, Kwan Sik Lee, Mi Na Kim대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제3호Current role of systemic therapy in transarterial chemotherapy-refractory hepatocellular carcinoma patientsHansung Kang, Hye Won Lee소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2021 · 제10권 제4호Recent advances in the management of hepatocellular carcinomaAndrew E. Hendifar, Arsen Osipov, Ekaterina K. Koltsova, Ju Dong Yang, Jun Gong, Kambiz Kosari, Kamya Sankar, Nicholas N. Nissen, Steven A. Miles대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제1호Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest?박준용, Hye Won Lee, Kyung Joo Cho대한면역학회 · Immune Network2020 · 제20권 제1호진행성 간세포암종의 새로운 면역 항암 치료유정주, 최현빈대한내과학회 · 대한내과학회지2025 · 제100권 제3호

이 간행물의 다른 논문 (22건)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernityJoon Ho Moon, 김원, Gi-Ae Kimpp. 831-843Waiting for the changes after the adoption of steatotic liver disease전대원, Eileen L. Yoonpp. 844-850Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapyTakako Inoue, Yasuhito Tanaka, Takehisa Watanabepp. 851-868Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harmYao-Chun Hsu, Jia-Horng Kao, Cheng-Hao Tsengpp. 869-890Hepatorenal syndrome: Current concepts and future perspectivesChan-Young Jung, Jai Won Changpp. 891-908
원문 보기